SMLR Stock Analysis
SM
Neutral
Based on Eyestock quantitative analysis, SMLR`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. The company is headquartered in Santa Clara, California and currently employs 124 full-time employees. The company went IPO on 2014-02-27. The firm develops, manufactures, and markets products and services that assist its customers in evaluating and treating chronic diseases. Its vascular testing product, QuantaFlo, measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (PAD). QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patient's vascular condition, including assessments of patients who have vascular disease. The company also has a distribution arrangement for the United States, including Puerto Rico, to distribute Insulin Insights, a software solution designed to provide insulin dosing recommendations to clinicians for the adjustment and maintenance of blood. The firm's customers for QuantaFlo include insurance plans, physician groups, and risk assessment groups.